DiabeteScan

A new resource for HCPs caring for people with diabetes!

DiabeteScan is your monthly appointment with the latest articles from the international diabetes literature.

Find out what relevant articles have been published in the last few weeks, and what impact they may have on your day-to-day practice.

Exclusively available on InfoDiabetes.education

Download slides

Cited in this episode of DiabeteScan:

• Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89.
  Wamil M, Coleman RL, Adler AI, et al. Diabetes Care 2021;44:1-8. 
• Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
  Gerstein HC, Sattar N, Rosenstock J, et al.; for the AMPLITUDE-O Trial Investigators. N Engl J Med 2021; doi: 10.1056/NEJMoa2108269. 
• Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes
  Filippatos G, Bakris GL, Pitt B, et al.; on behalf of the FIDELIO-DKD Investigators. J Am Coll Cardiol 2021;78:142-52 

Download slides

Cited in this episode of DiabeteScan:

• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
  Davies M, Færch L, Jeppesen OK, et al. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
  Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;10.1056/NEJMoa2107519. doi:10.1056/NEJMoa2107519 [published online ahead of print, 2021 Jun 25]
• Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
  Giugliano D, Longo M, Caruso P, et al. Diabetes Care. 2021;dc202623. doi:10.2337/dc20-2623. [published online ahead of print, 2021 Apr 21]

Download slides

Cited in this episode of DiabeteScan:

• Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
  Khunti K, Knighton P, Zaccardi F, et al. Lancet Diabetes Endocrinol. 2021;9(5):293-303. doi:10.1016/S2213-8587(21)00050-4
• Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus
  Fralick M, Colacci M, Thiruchelvam D, Gomes T, Redelmeier DA. Diabetes Obes Metab. 2021;23(4):950-960. doi:10.1111/dom.14300
• Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
  Lugner M, Sattar N, Miftaraj M, et al. Cardiovasc Diabetol. 2021;20(1):67. Published 2021 Mar 22. doi:10.1186/s12933-021-01258-x

Download slides

Cited in this episode of DiabeteScan:

• Once-Weekly Semaglutide in Adults with Overweight or Obesity
  Wilding et al. N Engl J Med 2021;384:989 
• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
  Davies et al. Lancet 2021;397:971–84
• Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
  Khunti et al. Lancet Diabetes Endocrinol 2021; https://doi.org/10.1016/ S2213-8587(21)00050-4 

Download slides

Cited in this episode of DiabeteScan:

• Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
  Patorno E, et al. Diabetes Care 2021;44(3):826-835.
• Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
  Xie Y, et al. Diabetes Care 2020;43(11):2859-2869.
• Sustained Intensive Treatment and Long-term Effects on HbA 1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI
  Lind M, et al. Diabetes Care 2021;44(1):141-14.

Download slides

Cited in this episode of DiabeteScan:

• Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
  Nanayakkara N, et al. Diabetologia 2021;64:275–87. 
• Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
  Zaccardi F, et al. Diabetes Care 2020;dc202080.
• Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58
  Cahn A, et al. Diabetes Obes Metab 2021;23:29–38.